Legend Biotech Corporation (LEGN)

NASDAQ: LEGN · IEX Real-Time Price · USD
56.93
+1.03 (1.84%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Company Description

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.

Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).

The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.

It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel.

The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Legend Biotech Corporation
Legend Biotech logo
Country United States
Founded 2014
IPO Date Jun 5, 2020
Industry Biotechnology
Sector Healthcare
Employees 1,826
CEO Dr. Ying Huang Ph.D.

Contact Details

Address:
2101 Cottontail Lane
Somerset, New Jersey 08873
United States
Phone 732-317-5050
Website legendbiotech.com

Stock Details

Ticker Symbol LEGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $23.00
CIK Code 0001801198
CUSIP Number 52490G102
ISIN Number US52490G1022
SIC Code 2834

Key Executives

Name Position
Dr. Ying Huang Ph.D. Chief Executive Officer and Director
Doug Wallace Vice President of Global Operations
Dr. Guowei Fang Ph.D. Chief Scientific Officer and Head of Business Development
Joanne Choi Senior Manager of Investor Relations
James Pepin J.D. General Counsel
Deborah Wong Executive Director of Strategic Marketing and Corporate Communications
Elaine Qian Vice President and Global Head of Human Resources
Dr. Yuhong Qiu Ph.D. Senior Vice President of Global Regulatory Affairs
Steven J. Gavel Senior Vice President of Commercial Development, US and Europe
Alan Kick Senior Vice President of Global Quality

Latest SEC Filings

Date Type Title
Mar 27, 2024 144 Filing
Mar 26, 2024 144 Filing
Mar 25, 2024 144 Filing
Mar 25, 2024 144 Filing
Mar 19, 2024 144 Filing
Mar 19, 2024 F-3ASR Filing
Mar 19, 2024 20-F Annual and transition report of foreign private issuers
Mar 15, 2024 6-K Report of foreign issuer
Mar 13, 2024 6-K Report of foreign issuer
Mar 11, 2024 6-K Report of foreign issuer